Printer-friendly versionPrinter-friendly version

A New Era for Screening and Treatment of Hepatitis C: A Public Health Challenge"

November 14-15, 2013- Split, Croatia

Thursday, November 14, 2013

Session 1 Opening and objectives
Chair: Tatjana Reic, John Ward

08.30 - 08.45

  • Welcome and opening
  • Introduction of the participants
  • Introduction of the VHPB. 1.8 Mb(.pdf) by Pierre Van Damme
  • Objectives of the meeting:
    • Give an overview of the current and future hepatitis C therapy developments and their use in controlling of hepatitis C;
    • Provide an overview of the status of the development of prophylactic and therapeutic hepatitis C vaccine;
    • Review of country examples of the current screenings strategies and their impact on the public health;
    • Identify barriers to identification and treatment of patients with hepatitis C, and discuss equal access to treatment, and point of view of the different stakeholders (hepatologist, patients, public health);
    • Examine the impact of the increasing amount of patients looking for help on the public health resources (financial and human resources).
  • Pre-meeting document 436KB (.pdf)

Session 2 Hepatitis C situation
Chair: Tatjana Reic, John Ward

not presented
Presentation on epidemiology of hepatitis C in Europe- incidence, risk population, prevalence, disease burden (cirrhosis, HCC) and mortality.(slides were distributed) 555kB(.pdf)
Erika Duffell, (ECDC – Stockholm, Sweden)

09.00 – 09.20
Hepatitis C in United States. 1.7MB(.pdf)
John Ward , (CDC- Atlanta, USA)

09.20 – 09.30 Discussion

Session 3 New hepatitis C era: changing therapy landscape
Chair: Françoise Roudot-Thoraval, Rui Tato Marinho

09.30 – 09.50
Overview of current developments in treatment of hepatitis C. 2.3MB(.pdf)
Jake Liang , (National Institutes of Health, Bethesda, USA)

09.50 – 10.10
Hepatitis C therapy : lessons learned from the first experience in a real world setting. 1.4MB (.pdf)
Benjamin Maasoumy , (Hannover Medical School, Germany)

10.10 – 10.30
Market access and uptake of new antiviral drugs for the treatment of hepatitis. 571kB (.pdf)
Homie Razavi , (Center for Disease Analysis, Colorado, USA)

10.30 – 10.45 Discussion

10.45 – 11.05 Coffee Break

Session 4 Review of current hepatitis C therapy guidelines
Chair: Johannes Hallauer, Selim Badur

11.05 – 11.25
EASL Clinical Practice Guidelines: management of hepatitis C virus infection and the adaptations needed.
Markus Peck-Radosavljevic, (Secretary General, EASL)

11.25 – 11.45
WHO Hepatitis C Therapeutic guidelines (they will be released before the end of 2013). 830kB (.pdf)
Stefan Wiktor, (WHO- Global Hepatitis Program)

11.45 – 12.05 Discussion

12.05 – 13.15 Lunch

Session 5 Impact of screening and care on public health and burden of disease.
Chair: Alessandro Zanetti, Vana Papaevangelou

13.15 – 13.35
Hepatitis C Screening: Key Issues and Evidence. 28kB (.pdf)
David Goldberg , (Health Protection Scotland, UK)

13.35 – 13.55
HCV Testing Strategies and New Patient Identification in the United States. 282kB (.pdf)
David Rein, (NORC at University of Chicago, USA)

13.55 – 14.15
USA: Public health impact of antiviral therapy for hepatitis C in the United States. 103Kb (.pdf)
Michael Volk , (University of Michigan, USA)

14.15– 14.35
Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis in Europe. 538kB (.pdf)
Homie Razavi , (Center for Disease Analysis, Colorado, USA)

14.35 – 14.55 Discussion

14.55 – 15.15 Coffee Break

Session 6 Country examples of national Hepatitis C controlling programmes
Chair: Heléne Norder, Stefan Wiktor

15.15 – 15.35
Croatia. 948kB(.pdf)
Tatjana Reic/ Prof Raiko Ostojic, (Croatia)

15.35– 15.55
The Netherlands: Hepatitis C treatment guidelines. 1.5MB (.pdf)
Floor Berden , (Radboud University Medical Centre, the Netherlands)

15.55 – 16.15
Sweden: Swedish Consensus Group. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. 174kB (.pdf)
Martin Lagging , (University of Gothenburg, Sweden)

16.15 – 16.35
Mediterranean and Balkan countries: executive summary of the Conference on Hepatitis B and C in Mediterranean and Balkan Countries, Nicosia, Cyprus 5-7 December 2012, organised by hepatitis B and C policy association. (focus on hepatitis C). 375kB(.pdf)
Spilios Manolakopoulos, (Greece –Hepatitis B and C policy association)

Chair: Mira Kojouharova, Wolfgang Jilg

16.55 – 17.25
Prospects for prophylactic and Therapeutic vaccines against the hepatitis C viruses in the world of improving treatment. 4.3MB(.pdf)
Jake Liang, (USA)

17.25– 17.35 Discussion


Friday, March 15, 2013

Chair: Paolo Bonanni, Angela Dominguez

09.00 – 09.20
Lessons learned from the treatment as prevention approach for HiV applicable to HCV. 6MB (.pdf)
Julio Montaner , (Professor of Medicine and Director, BC Centre for Excellence in HIV/AIDS).


09.20 – 09.40
Prevention of Hepatitis C Virus transmission Among People Who Inject Drugs. 1.2MB(.pdf)
Sharon Hutchinson , (Glasgow Caledonian University, Glasgow, Scotland, UK)

09.40 – 10.00 Discussion

Chair: Mark Kane, Pierre Van Damme

10.00 – 10.20
Barriers to hepatitis C treatment. 1.2MB(.pdf)
Philip Bruggmann , (ARUD Zurich, Switzerland)

10.20 – 11.30 Coffee Break


10.30 – 11.45


  • Group 1: point of view of Patients - Chair: Tatjana Reic/ Achim Kautz
  • Group 2: point of view of Policy Makers - Chair: Daniel Lavanchy/ Luidmilla Mosina
  • Group 3: Group 3: point of view of treating physicians - Chair: Daniel Shouval/Rui Tato Marinho
  • Group 4: point of view of industry


11.45 – 12.30 Plenary Feedback of the workshops

12.30 – 12.45 Discussion

13.00 – 14.30 Lunch

Session 9 Conclusions
Chair: Daniel Lavanchy, David Goldberg

14.30 – 15.30
Presentation of the VHPB meeting conclusions. 55kB(.pdf)
David FitzSimons

15.30 Close of the meeting